Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Arrowhead Pharmaceuticals Inc

ARWR
Current price
23.92 USD -1.44 USD (-5.68%)
Last closed 24.88 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 090 095 872 USD
Yield for 12 month -27.03 %
1Y
3Y
5Y
10Y
15Y
ARWR
21.11.2021 - 28.11.2021

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California. Address: 177 East Colorado Boulevard, Pasadena, CA, United States, 91105

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

53.77 USD

P/E ratio

Dividend Yield

Current Year

+240 735 000 USD

Last Year

+243 231 000 USD

Current Quarter

Last Quarter

+3 551 000 USD

Current Year

+228 242 000 USD

Last Year

+243 231 000 USD

Current Quarter

-4 525 000 USD

Last Quarter

-712 000 USD

Key Figures ARWR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -457 846 016 USD
Operating Margin TTM -1335.58 %
PE Ratio
Return On Assets TTM -32.07 %
PEG Ratio -1.32
Return On Equity TTM -99.43 %
Wall Street Target Price 53.77 USD
Revenue TTM 35 473 000 USD
Book Value 3.9 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -94.3 %
Dividend Yield
Gross Profit TTM 240 735 000 USD
Earnings per share -4.23 USD
Diluted Eps TTM -4.23 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY 9.8 %
Profit Margin

Dividend Analytics ARWR

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ARWR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 17.11.2011
Dividend Date

Stock Valuation ARWR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 111.1111
Enterprise Value Revenue 16.279
Price Sales TTM 16.8386
Enterprise Value EBITDA -11.0198
Price Book MRQ 19.0781

Financials ARWR

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ARWR

For 52 weeks

20.67 USD 39.83 USD
50 Day MA 25.11 USD
Shares Short Prior Month 9 613 661
200 Day MA 28.08 USD
Short Ratio 10.86
Shares Short 9 343 977
Short Percent 9.08 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

430.16 USD Microsoft Corporation +3.16 (+0.74%)
Detailed analytics

ETF funds


S

SX7EEX

14.70 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.1 (+0.64%)
Detailed analytics

Metals


Gold

2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics